


### Amendments to the Claims

1-71. (Canceled).

72. (Currently amended) A compound having the structural formula (A),



wherein:

- the dotted lines represent an optional double bond, provided that no two double bonds are adjacent to one another, and that the dotted lines represent at least 3, ~~optionally~~ 4 double bonds;
- $R^1$  is selected from the group consisting of ~~hydrogen~~, aryl, heterocycle,  $C_1$ - $C_{10}$  alkoxy,  $C_1$ - $C_{10}$  thioalkyl,  $C_1$ - $C_{10}$  alkyl-amino,  $C_1$ - $C_{10}$  dialkylamino,  $C_{3-10}$  cycloalkyl,  $C_{4-10}$  cycloalkenyl, and  $C_{4-10}$  cycloalkynyl, wherein each is ~~are~~ optionally substituted with one or more  $R^6$ ;
- Y is selected from a single bond, O,  $S(O)_m$ ,  $NR^{11}$ ,  $C_{1-10}$  alkylene,  $C_{2-10}$  alkenylene, or  $C_{2-10}$  alkynylene, wherein each alkylene, alkenylene or alkynylene optionally includes 1 to 3 heteroatoms selected from O, S or N; ~~provided that  $YR^1$  is not hydrogen or  $C_{1-6}$ -alkyl;~~
- $R^2$  and  $R^4$  are independently selected from the group consisting of hydrogen,  $C_{1-18}$  alkyl,  $C_{2-18}$  alkenyl,  $C_{2-18}$  alkynyl,  $C_{1-18}$  alkoxy,  $C_{1-18}$  alkylthio, halogen, -OH, -CN, -NO<sub>2</sub>, -NR<sup>7</sup>R<sup>8</sup>, haloalkyloxy, haloalkyl, -C(=O)R<sup>9</sup>, -C(=S)R<sup>9</sup>, -SH, aryl, aryloxy, arylthio, arylalkyl,  $C_{1-18}$  hydroxyalkyl,  $C_{3-10}$  cycloalkyl,  $C_{3-10}$  cycloalkyloxy,  $C_{3-10}$  cycloalkylthio,  $C_{3-10}$  cycloalkenyl,  $C_{7-10}$  cycloalkynyl, or


- and heterocycle, provided that or when one of  $R^{25}$  or  $R^{26}$  is present, then either  $R^2$  or  $R^4$  is selected from the group consisting of  $(=O)$ ,  $(=S)$ , and  $=NR^{27}$ ;
- X is selected from the group consisting of  $C_{1-10}$  alkylene,  $C_{2-10}$  alkenylene or and  $C_{2-10}$  alkynylene, where each optionally includes one or more heteroatoms selected from the group consisting of O, S, or N, provided any such heteroatom is not adjacent to the N in the imidazopyridyl ring;
  - m is any integer from 0 to 2;
  - $R^3$  is a heterocycle substituted with one or more  $R^{17}$ , provided that  $R^3$  optionally substituted with at least one  $R^{17}$  is not pyridinyl or 5-chlorothieryl;
  - $R^5$  is selected from the group consisting of hydrogen,  $C_{1-18}$  alkyl,  $C_{2-18}$  alkenyl,  $C_{2-18}$  alkynyl,  $C_{1-18}$  alkoxy,  $C_{1-18}$  alkylthio, halogen,  $-OH$ ,  $-CN$ ,  $-NO_2$ ,  $-NR^7R^8$ , haloalkyloxy, haloalkyl,  $-C(=O)R^9$ ,  $-C(=O)OR^9$ ,  $-C(=S)R^9$ ,  $SH$ , aryl, aryloxy, arylthio, arylalkyl,  $C_{1-18}$  hydroxyalkyl,  $C_{3-10}$  cycloalkyl,  $C_{3-10}$  cycloalkyloxy,  $C_{3-10}$  cycloalkylthio,  $C_{3-10}$  cycloalkenyl,  $C_{7-10}$  cycloalkynyl, or and heterocycle;
  - each  $R^6$  is independently selected from the group consisting of hydrogen,  $C_{1-18}$  alkyl,  $C_{2-18}$  alkenyl,  $C_{2-18}$  alkynyl,  $C_{1-18}$  alkoxy,  $C_{1-18}$  alkylthio,  $C_{1-18}$  alkylsulfoxide,  $C_{1-18}$  alkylsulfone,  $C_{1-18}$  halo-alkyl,  $C_{2-18}$  halo-alkenyl,  $C_{2-18}$  halo-alkynyl,  $C_{1-18}$  halo-alkoxy,  $C_{1-18}$  halo-alkylthio,  $C_{3-10}$  cycloalkyl,  $C_{3-10}$  cycloalkenyl,  $C_{7-10}$  cycloalkynyl, halogen,  $-OH$ ,  $-CN$ , cyanoalkyl,  $-CO_2R^{18}$ ,  $-NO_2$ ,  $-NR^7R^8$ ,  $C_{1-18}$  haloalkyl,  $-C(=O)R^{18}$ ,  $-C(=S)R^{18}$ ,  $-SH$ , aryl, aryloxy, arylthio, arylsulfoxide, arylsulfone, arylsulfonamide, aryl( $C_{1-18}$ )alkyl, aryl( $C_{1-18}$ )alkyloxy, aryl( $C_{1-18}$ )alkylthio, heterocycle and  $C_{1-18}$  hydroxyalkyl, where each is optionally substituted with one or more  $R^{19}$ ;
  - $R^7$  and  $R^8$  are independently selected from the group consisting of hydrogen,  $C_{1-18}$  alkyl,  $C_{1-18}$  alkenyl, aryl,  $C_{3-10}$  cycloalkyl,  $C_{4-10}$  cycloalkenyl, heterocycle,  $-C(=O)R^{12}$ ,  $-C(=S)R^{12}$ , and an amino acid residue linked through a carboxyl group thereof, or  $R^7$  and  $R^8$  are taken together with the nitrogen to form a heterocycle;


- $R^9$  and  $R^{18}$  are independently selected from the group consisting of hydrogen, -OH,  $C_{1-18}$  alkyl,  $C_{2-18}$  alkenyl,  $C_{3-10}$  cycloalkyl,  $C_{4-10}$  cycloalkenyl,  $C_{1-18}$  alkoxy, - $NR^{15}R^{16}$ , aryl, an amino acid residue linked through an amino group of the amino acid,  $-CH_2OCH(=O)R^{9a}$ , ~~or~~ and  $-CH_2OC(=O)OR^{9a}$  where  $R^{9a}$  is  $C_1-C_{12}$  alkyl,  $C_6-C_{20}$  aryl,  $C_6-C_{20}$  alkylaryl or  $C_6-C_{20}$  aralkyl;
- ~~$R^{10}$  and  $R^{11}$  are independently~~ is selected from the group consisting of hydrogen,  $C_{1-18}$  alkyl,  $C_{2-18}$  alkenyl,  $C_{3-10}$  cycloalkyl,  $C_{4-10}$  cycloalkenyl, aryl,  $-C(=O)R^{12}$ , heterocycle, ~~or~~ and an amino acid residue;
- $R^{12}$  is selected from the group consisting of hydrogen,  $C_{1-18}$  alkyl,  $C_{2-18}$  alkenyl, aryl,  $C_{3-10}$  cycloalkyl,  $C_{4-10}$  cycloalkenyl, ~~or~~ and an amino acid residue;
- $R^{15}$  and  $R^{16}$  are independently selected from the group consisting of hydrogen,  $C_{1-18}$  alkyl,  $C_{2-18}$  alkenyl,  $C_{2-18}$  alkynyl, aryl,  $C_{3-10}$  cycloalkyl,  $C_{4-10}$  cycloalkenyl, ~~or~~ and an amino acid residue;
- each  $R^{17}$  is independently selected from the group consisting of hydrogen,  $C_{1-18}$  alkyl,  $C_{2-18}$  alkenyl,  $C_{2-18}$  alkynyl,  $C_{1-18}$  alkoxy,  $C_{1-18}$  alkylthio,  $C_{1-18}$  alkylsulfoxide,  $C_{1-18}$  alkylsulfone,  $C_{2-18}$  halogenated alkenyl,  $C_{2-18}$  halogenated alkynyl,  $C_{2-18}$  halogenated alkoxy,  $C_{1-18}$  halogenated alkylthio,  $C_{3-10}$  cycloalkyl,  $C_{3-10}$  cycloalkenyl,  $C_{7-10}$  cycloalkynyl, halogen, OH, CN,  $NO_2$ ,  $NR^7R^8$ , haloalkyl,  $C(=O)R^{18}$ ,  $C(=S)R^{18}$ , SH, aryl, arylloxy, arylthio,  $CO_2H$ ,  $CO_2R^{18}$ , arylsulfoxide, arylsulfone, arylsulfonamide, arylalkyl, arylalkyloxy, arylalkylthio, heterocyclic, and  $C_{1-18}$  hydroxyalkyl, where each of said aryl, arylloxy, arylthio, arylalkyl, arylalkyloxy, arylalkylthio, heterocycle,  $C_{1-18}$  hydroxyalkyl, arylsulfoxide, arylsulfone, or arylsulfonamide is optionally substituted with one or more  $R^{19}$ ;
- each  $R^{19}$  is independently selected from the group consisting of hydrogen,  $C_{1-18}$  alkyl,  $C_{2-18}$  alkenyl,  $C_{2-18}$  alkynyl,  $C_{1-18}$  alkoxy,  $C_{2-18}$  alkenyloxy,  $C_{2-18}$  alkynyloxy,  $C_{1-18}$  alkylthio,  $C_{3-10}$  cycloalkyl,  $C_{4-10}$  cycloalkenyl,  $C_{4-10}$  cycloalkynyl, halogen, -OH, -CN, cyanoalkyl,  $-NO_2$ ,  $-NR^{20}R^{21}$ ,  $C_{1-18}$  haloalkyl,  $C_{1-18}$  haloalkyloxy,  $-C(=O)R^{18}$ ,  $-C(=O)OR^{18}$ ,  $-OalkenylC(=O)OR^{18}$ ,

- OalkylC(=O)NR<sup>20</sup>R<sup>21</sup>, -OalkylOC(=O)R<sup>18</sup>, -C(=S)R<sup>18</sup>, SH, -C(=O)N(C<sub>1-6</sub> alkyl), -N(H)S(O)(O)(C<sub>1-6</sub> alkyl), aryl, heterocycle, C<sub>1-18</sub> alkylsulfone, arylsulfoxide, arylsulfonamide, aryl(C<sub>1-18</sub>)alkyloxy, aryloxy, aryl(C<sub>1-18</sub> alkyl)oxy, arylthio, aryl(C<sub>1-18</sub>)alkylthio ~~or~~ and aryl(C<sub>1-18</sub>)alkyl, where each is optionally substituted with 1 or more =O, -NR<sup>20</sup>R<sup>21</sup>, -CN, C<sub>1-18</sub> alkoxy, heterocycle, C<sub>1-18</sub> haloalkyl, heterocycle alkyl, heterocycle connected to R<sup>17</sup> by alkyl, alkoxyalkoxy or halogen;
- R<sup>20</sup> and R<sup>21</sup> are independently selected from the group consisting of hydrogen, C<sub>1-18</sub> alkyl, C<sub>2-18</sub> alkenyl, C<sub>2-18</sub> alkynyl, aryl, C<sub>3-10</sub> cycloalkyl, C<sub>4-10</sub> cycloalkenyl, -C(=O)R<sup>12</sup>, carboxylester-substituted heterocycle, ~~or~~ and -C(=S)R<sup>12</sup>;
  - R<sup>25</sup> and R<sup>26</sup> are not present, or are independently selected from the group consisting of hydrogen, C<sub>1-18</sub> alkyl, C<sub>3-10</sub> cycloalkyl, aryl and heterocycle, where each is optionally independently substituted with 1 to 4 of C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, halo, -CH<sub>2</sub>OH, benzyloxy, and -OH; and
  - R<sup>27</sup> is selected from the group consisting of hydrogen, C<sub>1-18</sub> alkyl, C<sub>3-10</sub> cycloalkyl, (C<sub>3-10</sub> cycloalkyl)-C<sub>1-6</sub> alkyl, aryl, and aryl(C<sub>1-18</sub>)alkyl; and salts, tautomers, and stereoisomers ~~and solvates~~ thereof.

73. – 78. (Cancelled)

79. (Currently amended) A compound having the structural formula (C) (A)





wherein:

- the dotted lines represent an optional double bond, provided that no two double bonds are adjacent to one another, and that the dotted lines represent at least 3, optionally 4 double bonds;
- $R^1$  is selected from the group consisting of hydrogen, aryl, heterocycle,  $C_1$ - $C_{10}$  alkoxy,  $C_1$ - $C_{10}$  thioalkyl,  $C_1$ - $C_{10}$  alkyl-amino,  $C_1$ - $C_{10}$  dialkylamino,  $C_{3-10}$  cycloalkyl,  $C_{4-10}$  cycloalkenyl, and  $C_{4-10}$  cycloalkynyl, wherein each are is optionally substituted with one or more  $R^6$ ;
- Y is selected from a single bond, O,  $S(O)_m$ ,  $NR^{11}$ ,  $C_{1-10}$  alkylene,  $C_{2-10}$  alkenylene, or  $C_{2-10}$  alkynylene, wherein each alkylene, alkenylene or alkynylene optionally includes 1 to 3 heteroatoms selected from O, S or N; provided that  $YR^1$  is not hydrogen or  $C_{1-6}$ -alkyl;
- $R^2$  and  $R^4$  are independently selected from the group consisting of hydrogen,  $C_{1-18}$  alkyl,  $C_{2-18}$  alkenyl,  $C_{2-18}$  alkynyl,  $C_{1-18}$  alkoxy,  $C_{1-18}$  alkylthio, halogen, -OH, -CN, - $NO_2$ , - $NR^7R^8$ , haloalkyloxy, haloalkyl, - $C(=O)R^9$ , - $C(=S)R^9$ , -SH, aryl, aryloxy, arylthio, arylalkyl,  $C_{1-18}$  hydroxyalkyl,  $C_{3-10}$  cycloalkyl,  $C_{3-10}$  cycloalkyloxy,  $C_{3-10}$  cycloalkylthio,  $C_{3-10}$  cycloalkenyl,  $C_{7-10}$  cycloalkynyl, or and heterocycle, provided that when one of  $R^{25}$  or  $R^{26}$  is present, then either  $R^2$  or  $R^4$  is selected from the group consisting of  $(=O)$ ,  $(=S)$ , and  $=NR^{27}$ ;
- X is selected from the group consisting of  $C_1$ - $C_{10}$  alkylene,  $C_{2-10}$  alkenylene or and  $C_{2-10}$  alkynylene, where each optionally includes one or more heteroatoms

selected from the group consisting of O, S, or N, provided any such heteroatom is not adjacent to the N in the imidazopyridyl ring;

- m is any integer from 0 to 2;
- $R^3$  is a 4-, 7-, 8- or 9-membered aryl, aryloxy, arylthio, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl-N( $R^{10}$ )-, or heterocycle, each of which is optionally substituted with one or more  $R^{17}$ , provided that for cycloalkenyl the double bond is not adjacent to a nitrogen, provided M-Q- $R^3$  is not biphenyl, and provided that  $R^3$  substituted with at least one  $R^{17}$  is not pyridinyl or 5-chlorothieryl;
- $R^5$  is selected from the group consisting of hydrogen,  $C_{1-18}$  alkyl,  $C_{2-18}$  alkenyl,  $C_{2-18}$  alkynyl,  $C_{1-18}$  alkoxy,  $C_{1-18}$  alkylthio, halogen, -OH, -CN, -NO<sub>2</sub>, -NR<sup>7</sup>R<sup>8</sup>, haloalkyloxy, haloalkyl, -C(=O)R<sup>9</sup>, -C(=O)OR<sup>9</sup>, -C(=S)R<sup>9</sup>, -SH, aryl, aryloxy, arylthio, arylalkyl,  $C_{1-18}$  hydroxyalkyl,  $C_{3-10}$  cycloalkyl,  $C_{3-10}$  cycloalkyloxy,  $C_{3-10}$  cycloalkylthio,  $C_{3-10}$  cycloalkenyl,  $C_{7-10}$  cycloalkynyl, or and heterocycle;
- each  $R^6$  is independently selected from the group consisting of hydrogen,  $C_{1-18}$  alkyl,  $C_{2-18}$  alkenyl,  $C_{2-18}$  alkynyl,  $C_{1-18}$  alkoxy,  $C_{1-18}$  alkylthio,  $C_{1-18}$  alkylsulfoxide,  $C_{1-18}$  alkylsulfone,  $C_{1-18}$  halo-alkyl,  $C_{2-18}$  halo-alkenyl,  $C_{2-18}$  halo-alkynyl,  $C_{1-18}$  halo-alkoxy,  $C_{1-18}$  halo-alkylthio,  $C_{3-10}$  cycloalkyl,  $C_{3-10}$  cycloalkenyl,  $C_{7-10}$  cycloalkynyl, halogen, -OH, -CN, cyanoalkyl, -CO<sub>2</sub>R<sup>18</sup>, -NO<sub>2</sub>, -NR<sup>7</sup>R<sup>8</sup>,  $C_{1-18}$  haloalkyl, -C(=O)R<sup>18</sup>, -C(=S)R<sup>18</sup>, -SH, aryl, aryloxy, arylthio, arylsulfoxide, arylsulfone, arylsulfonamide, aryl( $C_{1-18}$ )alkyl, aryl( $C_{1-18}$ )alkyloxy, aryl( $C_{1-18}$ )alkylthio, heterocycle and  $C_{1-18}$  hydroxyalkyl, where each is optionally substituted with one or more  $R^{19}$ ;
- $R^7$  and  $R^8$  are independently selected from the group consisting of hydrogen,  $C_{1-18}$  alkyl,  $C_{1-18}$  alkenyl, aryl,  $C_{3-10}$  cycloalkyl,  $C_{4-10}$  cycloalkenyl, heterocycle, -C(=O)R<sup>12</sup>, -C(=S)R<sup>12</sup>, and an amino acid residue linked through a carboxyl group thereof, or  $R^7$  and  $R^8$  are taken together with the nitrogen to form a heterocycle;

- $R^9$  and  $R^{18}$  are independently selected from the group consisting of hydrogen, -OH,  $C_{1-18}$  alkyl,  $C_{2-18}$  alkenyl,  $C_{3-10}$  cycloalkyl,  $C_{4-10}$  cycloalkenyl,  $C_{1-18}$  alkoxy,  $-NR^{15}R^{16}$ , aryl, an amino acid residue linked through an amino group of the amino acid,  $-CH_2OCH(=O)R^{9a}$ , ~~or~~ and  $-CH_2OC(=O)OR^{9a}$  where  $R^{9a}$  is  $C_{1-12}$  alkyl,  $C_6-C_{20}$  aryl,  $C_6-C_{20}$  alkylaryl or  $C_6-C_{20}$  aralkyl;
- $R^{10}$  and  $R^{11}$  are independently selected from the group consisting of hydrogen,  $C_{1-18}$  alkyl,  $C_{2-18}$  alkenyl,  $C_{3-10}$  cycloalkyl,  $C_{4-10}$  cycloalkenyl, aryl,  $-C(=O)R^{12}$ , heterocycle, ~~or~~ and an amino acid residue;
- $R^{12}$  is selected from the group consisting of hydrogen,  $C_{1-18}$  alkyl,  $C_{2-18}$  alkenyl, aryl,  $C_{3-10}$  cycloalkyl,  $C_{4-10}$  cycloalkenyl, ~~or~~ and an amino acid residue;
- $R^{15}$  and  $R^{16}$  are independently selected from the group consisting of hydrogen,  $C_{1-18}$  alkyl,  $C_{2-18}$  alkenyl,  $C_{2-18}$  alkynyl, aryl,  $C_{3-10}$  cycloalkyl,  $C_{4-10}$  cycloalkenyl, ~~or~~ and an amino acid residue;
- each  $R^{17}$  is independently MQ- wherein M is a ring optionally substituted with one or more  $R^{19}$ , and Q is a bond or a linking group connecting M to  $R^3$  that has 1 to 10 atoms and is optionally substituted with one or more  $R^{19}$ ;
- each  $R^{19}$  is independently selected from the group consisting of hydrogen,  $C_{1-18}$  alkyl,  $C_{2-18}$  alkenyl,  $C_{2-18}$  alkynyl,  $C_{1-18}$  alkoxy,  $C_{2-18}$  alkenyloxy,  $C_{2-18}$  alkynyloxy,  $C_{1-18}$  alkylthio,  $C_{3-10}$  cycloalkyl,  $C_{4-10}$  cycloalkenyl,  $C_{4-10}$  cycloalkynyl, halogen, -OH, -CN, cyanoalkyl,  $-NO_2$ ,  $-NR^{20}R^{21}$ ,  $C_{1-18}$  haloalkyl,  $C_{1-18}$  haloalkyloxy,  $-C(=O)R^{18}$ ,  $-C(=O)OR^{18}$ ,  $-OalkenylC(=O)OR^{18}$ ,  $-OalkylC(=O)NR^{20}R^{21}$ ,  $-OalkylOC(=O)R^{18}$ ,  $-C(=S)R^{18}$ , -SH,  $-C(=O)N(C_{1-6}alkyl)$ ,  $-N(H)S(O)(O)(C_{1-6}alkyl)$ , aryl, heterocycle,  $C_{1-18}$  alkylsulfone, arylsulfoxide, arylsulfonamide, aryl( $C_{1-18}$ )alkyloxy, aryloxy, aryl( $C_{1-18}$ )alkyloxy, arylthio, aryl( $C_{1-18}$ )alkylthio or aryl( $C_{1-18}$ )alkyl, where each is optionally substituted with 1 or more =O,  $-NR^{20}R^{21}$ , -CN,  $C_{1-18}$  alkoxy, heterocycle,  $C_{1-18}$  haloalkyl, heterocycle alkyl, heterocycle connected to  $R^{17}$  by alkyl, alkoxyalkoxy ~~or~~ and halogen;

- R<sup>20</sup> and R<sup>21</sup> are independently selected from the group consisting of hydrogen, C<sub>1-18</sub> alkyl, C<sub>2-18</sub> alkenyl, C<sub>2-18</sub> alkynyl, aryl, C<sub>3-10</sub> cycloalkyl, C<sub>4-10</sub> cycloalkenyl, -C(=O)R<sup>12</sup>, or -C(=S)R<sup>12</sup>;
- ~~R<sup>25</sup> and R<sup>26</sup> are not present, or are independently selected from the group consisting of hydrogen, C<sub>1-18</sub> alkyl, C<sub>3-10</sub> cycloalkyl, aryl and heterocycle, where each is optionally independently substituted with 1 to 4 of C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, halo, -CH<sub>2</sub>OH, benzyloxy, and -OH; and~~
- ~~R<sup>27</sup> is selected from the group consisting of hydrogen, C<sub>1-18</sub> alkyl, C<sub>3-10</sub> cycloalkyl, (C<sub>3-10</sub> cycloalkyl)-C<sub>1-6</sub> alkyl, aryl, and aryl(C<sub>1-18</sub>)alkyl; and salts, tautomers, and stereoisomers and solvates thereof.~~

80. (Cancelled)

81. (Currently amended) A compound according to claim 72, wherein R<sup>3</sup> is isoxazolyl substituted with one to three R<sup>17</sup>.

82.-85. (Cancelled)

86. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound according to claim 72.

87. -89. (Cancelled)

90. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound according to claim 79.

91. (New) The compound of claim 72, wherein YR<sup>1</sup> is halophenyl or halomethyl-substituted phenyl.



92. (New) The compound of claim 91, wherein halophenyl is ortho-fluorophenyl.

93. (New) The compound of claim 72, wherein  $R^{17}$  is aryl or a heterocycle further substituted with 1, 2 or 3  $R^{19}$ .

94. (New) The compound of claim 72, wherein  $YR^1$  is not an unsubstituted  $C_{3-10}$  cycloalkyl.

95. (New) The compound of claim 72 wherein  $R^{19}$  is trihalomethyl, trihalomethoxy, alkoxy or halogen.

96. (New) The compound of claim 72, wherein  $R^1$  is aryl or aromatic heterocycle substituted with 1, 2 or 3  $R^6$  and wherein  $R^6$  is halogen,  $C_{1-18}$  alkoxy or  $C_{1-18}$  haloalkyl.

97. (New) The compound of claim 72, wherein Y is a bond.

98. (New) The compound of claim 72, wherein X is selected from the group consisting of  $-CH_2-$ ,  $-CH(CH_3)-$ ,  $-CH_2-CH_2-$ ,  $-CH_2-CH_2-CH_2-$ ,  $-CH_2-CH_2-CH_2-CH_2-$ ,  $-(CH_2)_{2,4}-O-(CH_2)_{2,4}-$ ,  $-(CH_2)_{2,4}-S-(CH_2)_{2,4}-$ ,  $-(CH_2)_{2,4}-NR^{10}-(CH_2)_{2,4}-$ ,  $C_{3-10}$  cycloalkylidene,  $C_{2-6}$  alkenylene and  $C_{2-6}$  alkynylene, wherein  $R^{10}$  is selected from the group consisting of hydrogen,  $C_{1-18}$  alkyl,  $C_{2-18}$  alkenyl,  $C_{3-10}$  cycloalkyl,  $C_{4-10}$  cycloalkenyl, aryl,  $-C(=O)R^{12}$ , heterocyclic, and an amino acid residue.

99. (New) The compound of claim 72, wherein X is methylene.

100. (New) The compound of claim 72, wherein  $R^3$  is a heterocycle substituted with 0 to 3  $R^{17}$ .

101. (New) The compound of claim 100, wherein the  $R^3$  is an aromatic heterocycle.

102. (New) The compound of claim 101, wherein the heterocycle contains 1, 2 or 3 N, S or O atoms in the ring, is linked to X through a ring carbon atom and contains 4 to 6 total ring atoms.

103. (New) The compound of claim 72, wherein  $R^{17}$  is selected from the group consisting of  $C_{3-10}$  cycloalkyl,  $C_{3-10}$  cycloalkenyl,  $C_{7-10}$  cycloalkynyl, aryl, aryloxy, arylthio, arylsulfoxide, arylsulfone, arylsulfonamide, arylalkyl; arylalkyloxy; arylalkylthio and heterocycle, each being unsubstituted or substituted with 1 or more  $R^{19}$ .

104. (New) The compound of claim 72, wherein  $R^9$  and  $R^{18}$  are H, OH or alkyl.

105. (New) The compound of claim 72, wherein  $R^5$  is H.

106. (New) The compound of claim 72, wherein  $R^6$  is halogen.

107. (New) The compound of claim 72, wherein  $R^7$ ,  $R^8$ ,  $R^{11}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{20}$ , and  $R^{21}$  are independently H or  $C_{1-18}$  alkyl.

108. (New) The compound of claim 72, wherein  $R^{12}$  is OH or alkyl.

109. (New) The compound of claim 72, wherein  $R^{19}$  is selected from the group consisting of H;  $C_{1-18}$  alkyl;  $C_{2-18}$  alkenyl;  $C_{2-18}$  alkynyl;  $C_{1-18}$  alkoxy; alkenyloxy; alkynyloxy;  $C_{1-18}$  alkylthio;  $C_{3-10}$  cycloalkyl;  $C_{4-10}$  cycloalkenyl;  $C_{4-10}$

cycloalkynyl; halogen; OH; CN; cyanoalkyl; NO<sub>2</sub>; NR<sup>20</sup>R<sup>21</sup>; haloalkyl; haloalkyloxy; C(=O)R<sup>18</sup>; C(=O)OR<sup>18</sup>; OalkenylC(=O)OR<sup>18</sup>; -OalkylC(=O)NR<sup>20</sup>R<sup>21</sup>; aryl; heterocycle; -OalkylOC(=O)R<sup>18</sup>; C(=O)N(C<sub>1-6</sub> alkyl), N(H)S(O)(O)(C<sub>1-6</sub> alkyl); arylalkyloxy; aryloxy; arylalkyloxy; and arylalkyl; each of which is unsubstituted or substituted with 1 or more =O; NR<sup>20</sup>R<sup>21</sup>; CN; alkoxy; heterocycle; haloalkyl- or alkyl-substituted heterocycle; and heterocycle linked to R<sup>17</sup> by alkyl; alkoxyalkoxy and halogen.

110. (New) The compound of claim 109, wherein R<sup>19</sup> is independently selected from the group consisting of halogen, NR<sup>20</sup>R<sup>21</sup>, alkoxy, halo-substituted alkyl and halo-substituted alkoxy.

111. (New) The compound of claim 72, wherein R<sup>25</sup> and R<sup>26</sup> are not present.

112. (New) The compound of claim 72, wherein haloalkyl or haloalkyloxy is -CF<sub>3</sub> or -OCF<sub>3</sub>.

113. (New) The compound of claim 72, wherein Y is a single bond, and R<sup>1</sup> is phenyl.

114. (New) The compound of claim 79, wherein Y is a single bond, and R<sup>1</sup> is aryl.

115. (New) The compound of claim 79, wherein X is C<sub>1</sub>-C<sub>10</sub> alkylene, C<sub>2-10</sub> alkenylene or C<sub>2-10</sub> alkynylene.

116. (New) The compound of claim 79, wherein R<sup>3</sup> is a heterocycle.

117. (New) The compound of claim 79, wherein R<sup>3</sup> is a heterocycle substituted with R<sup>17</sup> where Q is a bond and M is aryl.

118. (New) The compound of claim 79, wherein R<sup>3</sup> is isoxazole substituted with R<sup>17</sup> where Q is a bond and M is aryl.

119. (New) A method comprising administering to a subject in need of treatment or prophylaxis of a viral infection an anti-virally effective amount of a compound of claim 72 or claim 79.

120. (New) The method of claim 119, wherein the viral infection is an infection of a hepatitis-C virus.

121. (New) The method of claim 119, further comprising administering at least one additional antiviral therapy to the subject.

122. (New) The method of claim 121 wherein the additional therapy is selected from the group consisting of an interferon alpha and ribavirin.

123. (New) The method of claim 119, wherein the viral infection is an infection from a virus belonging to the family of the Flaviridae and the Picornaviridae.

124. (New) The method of claim 119, wherein the viral infection is an infection from a Coxsackie virus.

125. (New) The method of claim 119, wherein the viral infection is an infection from a Bovine Viral Diarrhea Virus.